GULF MEDICAL JOURNAL GMJ, ASM 2013;2(S1):S46-S53
|
|
- Beverly Morrison
- 6 years ago
- Views:
Transcription
1 Anti- VEGF injection for treatment of chronic central serous choridopathy: A case report Salwa Attia Department of Ophthalmology, GMC Hospital, Ajman, UAE ABSTRACT Objective: Central Serous Choridopathy (CSC) in an eye disease which causes visual impairment, often temporary, usually in one eye, mostly affects males in the age group 20 to 50 but which may also affect women 1,2. When the disorder is active it is characterized by leakage of fluid under the retina, re-accumulate under the central macula. This results in blurred vision with metamorphopsia. A blurred or gray spot in the central visual field is common when the retina is detached. Reduced visual acuity may persist after the fluid has disappeared. Material and Methods: A 36 years old male was presented to GMC Ophthalmology clinic with history of poor vision in his left eye since 7 years which was diagnosed as CSC at that time and general steroid treatment was given in dose of 80mg tabs daily for 2 weeks with no improvement and vision was stayed very poor in left eye since that time. On examination vision in left eye was 0.3 aided and no improvement by pinhole. OCT shows fusiform shaped space of sub macular oedema which was diagnosed by us as Lt chronic central serous retinopathy, Decision was made to inject him Intravitreal Anti VEGF in his left eye.oct, IOP and vision estimation was made before injection and three days after injection, then weekly for one month, monthly for 6months. Results: OCT after 3 days from injection shows complete absorption of the submacular fluid with improvement of vision more than 4 lines. Conclusion: Intravitreal Anti-VEGF proved to be an easy, safe and effective new method of CSC treatment even in chronic cases and comes to be superior to conventional methods of treatment like: o Laser photo coagulation o Transpupillary thermotherapy o Photodynamic therapy And this gives new indication added to the indications of use of intravitreal Anti-VFGF. Keywords: central serous choridopathy (CSC), anti-vegf INTRODUCTION Central serous chorioretinopathy (CSCR) is an idiopathic disorder characterized by neuroepithelial serous detachment, with or without concomitant pigment epithelium detachment (PED) and decompensated retinal pigment epithelium (RPE) associated with one or more focal active leakage sites (ALS) at the level of the RPE ( smoke-stack on fluorescein angiography (FA)). The underlying pathogenesis of CSCR is not thoroughly understood 1. Hypotheses on the pathogenesis of CSCR have ranged from a basic alteration in the choroid to an involvement of the retinal pigment epithelium (RPE). Starting from evidence that affected subjects often present a personality prone to stress with altered pituitary hypothalamic axis response (HPA) and they have higher levels of serum and urinary cortisol and catecholamines than healthy subjects, a cascade of events that may lead to CSCR through hypercoagulability and augmented platelet aggregation 2. This disease is common in males between 20 to 45 years of age 3. CSCR is more common in Caucasians, Hispanics and Asians, and less common in those of African descent 4. Choroidal circulation abnormalities (most likely choriocapillaris) precede disintegration of the RPE 5. The symptoms of CSCR are blurred vision, a dark spot in the center of the visual field; micropsia and metamorphopsia are all caused by anterior displacement of 46
2 the retinal plane after subretinal effusion due to porous RPE. Within 3 months resolution of CSC will happen in more than 50% of patients, with recovery of visual acuity (VA) despite some pigment epithelium scarring 6. Optical coherence tomography (OCT) examinations often reveal several PEDs that, when chronic, are associated with subretinal accumulation of fibrin, lipids, choriocapillaris atrophy, and choroidal neovascularization 1. A sectorial hypoperfusion will lead to vascular bed reduction due to vasoconstriction and this to capillary occlusion, accordingly increasing in the endoluminal pressure perfusion in the surrounding healthy vascular bed 7. The increased endoluminal pressure will lead to leakage of serum and small molecules in the stroma causing a further vascular tamponade. Since choroidal blood flow can be described by Hagen Poiseuille s law (ΔP = 8 μlq/πr 4 ), it follows that small differences in total radius of vascular bed induce a high increase in endovascular pressure with fluid extravasation and, in the same direction, a variation in viscosity (μ) determines a modification of choriocapillaris hemodynamics 8,9. The affinity of the disease for the macular area is due to the particular organization of the choriocapillaris with a closer meshwork than the peripheral choroid 10. The term acute CSC usually refers to the self-limiting CSC that resolves spontaneously over a few months without any treatment and minimal residual changes on imaging 11. Chronic CSC, meaning a serous macular elevation, visible biomicroscopically or detected by OCT, which is associated with RPE atrophic areas 4. The main difference between chronic and acute disease is the fact that chronic disease has widespread pigment epithelial changes without detachment, whereas in acute disease there is focal pigment epithelial abnormality and marked detachment. Photoreceptor atrophy in the fovea occurs after four months 11. Attenuation of the foveal photoreceptor layer is associated with permanent visual loss. Foveal photoreceptors damage which happens with chronic CSS signs could be considered as the high risk group of treatment should be applied 12. Only we consider considered treatment in recurrent chronic CSC or a single CSC episode, of greater than 3 months duration, with some signs of chronic CSC. Usually visual loss in the fellow eye caused due to similar procedure, in this case we must treat even in absence of chronic CSC 13. Patients usually present with a disturbance in central vision, a blind spot in the central field, metamorphopsia. ons to the retinal pigment epithelium. In the acute stage, there is an overlying elevation of the neurosensory retina 3. If the Figure 1: Previous Pharmacological and other Treatment Suggestions 47
3 subretinal fluid does not involve the central of macula or foveal region they will not feel any symptoms. If the neurosensory part of retina is displaced or become away from its source of nutrition, which is the choroidal circulation. Corticosteroids was the treatment of choice in CSC for several years either by the oral route or by local subconjuctivally, but are no longer recommended as knowledge of CSC pathogenesis has evolved Adrenocorticotropic hormone 15, antiinflammatory drugs 16, retrobulbartolazoline injections 17, subconjuctival injections of milk, albumin and salt solutions, antisyphilitic and anti-tubercular drugs, insulin-free pancreatic extract, and thyroid extract have all also been suggested in the past 18. The use of the above agents was not proven to be effective by any clinical trials 19. Carbonic anhydrase inhibitors are also tried for treating CSC with short-term encouraging results but no evidence of long-term benefit 20. Treatment options for CSC The Use of Argon Laser Photocoagulation (Focal photocoagulation of the leakage sites) A reduction in CSC recurrences and shortening of the duration of detachment with direct laser photocoagulation compared with sham or indirect (away from the site of leakage) 25,26. Untreated eyes were 3.3 times more prone to develop a recurrence than treated eyes. However, if the area of leakage is subfoveal or juxtafoveal, photocoagulation may induce secondary choroidal neovascularisation (CNV) and/or of damage foveal photoreceptors 27. Therefore other treatment options appear safer. Transpupillary Thermotherapy TTT in chronic CSC, which resulted in the resolution of CSC with subfoveal angiographic leaks and marked improvement in visual outcome. Photodynamic Treatment with Verteporfin has recently been utilized to treat ICSC. Both have an occlusive effect on CNV and also affect normal choroidal perfusion 28. Both Fluorescein and ICG-A-guided PDT have been recommended for treatment of ICSC 29. PDT acts by both decreasing choroidal hyperpermeability and by tightening the blood retinal barrier at the level of the RPE 30. Choroidal hypoperfusion, can also lead to some complications, like if conventional PDT is performed, according to the Treatment of age-related macular degeneration three cases of abrupt visual loss due to severe choroidalischaemia after using standard PDT in CSC patients 31,32. RPE atrophy, juxtafoveal CNV, and transient reduction in macular function 33,34. A hypothesis that VEGF antibodies could reduce choroidalhyperpermeability and choriocapillarisischaemia associated with CSC 35 resulted in treatment Figure 2: (a) OCT image of a CSC patient before intravitreal injection of (ranibizumab) showing a large amount of subretinal fluid involving the fovea. (b) OCT image of the same patient 3 months after treatment with intravitreal injection of (ranibizumab) showing complete resolution of subretinal fluid
4 of acute and chronic forms of CSC with intravitreal injection of (ranibizumaband of bevacizumab (Avastin) Larger, controlled trials are still needed to evaluate the efficacy and safety of anti- VEGF agents for this indication. Micropulse Diode Laser Photocoagulation (810 nm) has recently been assessed for the treatment of chronic CSC To avoid retinal damage, caused by conventional laser photocoagulation. It has been used in chronic CSC, in eyes with either well-defined leaking sites or diffuse leakage and proved to be safe from treatment of Chronic CSC. Subthreshold micropulse diode laser photocoagulation therefore appears to be a safe form of treatment in chronic CSC. Results however are not superior to PDT. Furthermore, micropulse diode laser photocoagulation seems unsuitable for diffuse leakage and diffuse RPE decompensation. These are frequent findings in chronic CSC cases. MATERIALS & METHODS History A 36 years old male was presented to GMC Ophthalmology clinic with history of drop of vision in his left eye since 7 years which was diagnosed at that time as acute CSC. General steroid treatment was given at that time in the form of oral tabs in a dose of 80mg per day for 2 weeks. No improvement was achieved at that time and vision stayed very poor in left eye since that time. On examination vision in left eye was 0.3 non-aided and no improvement with glasses, vision in Rt eye was 0.9 non aided. Our diagnosis started with a dilated examination of the retina, followed with confirmation by optical coherence tomography and fluorescein angiography. The old angiography showed one fluorescent spot with fluid leakage which appeared in a classic smoke stack shape. OCT shows fusiform shaped space of submacularoedema which was diagnosed by us as Lt chronic central serous chorio retinopathy. No history of use, of any exogenous corticosteroids (oral, topical, intranasal, and invasive) in the 6 months prior to the study, as well as no diabetic retinopathy, no uveitis, any hereditary retinal/macular disease, or history of intraocular surgery. Chronic CSC was defined as RPE leakage on FA persisting at least 3 months, with or without areas of diffuse RPE decompensation and corresponding subretinal fluid accumulation evidenced at OCT. Decision was made to inject him Intravitreal Anti VEGF in his left eye. OCT, IOP and vision estimation was made before injection and three days after injection, then every week for one month, then monthly for 6months. Patient ophthalmic examination, at baseline and at 6 weeks, 6 and 10 months after treatment, included slit-lamp biomicroscopy, indirect ophthalmoscopy, best-corrected visual acuity (BCVA), Amsler grid screening, Central Macular Thickness (CMT) with OCT, and FA after initial treatment. Applanation tonometry Keeler 2401-P was used to measure the intraocular pressure (IOP). The CMT at the foveola was assessed by OCT in the automated mode (line and retinal thickness map mode, Model 3D.OCT.2000 (FA plus), TOPCON, Japan ). FA was done with the use of (FA plus camera, TOPCON, Japan) and performed with 5 cc of 10% fluorescein (Fluorescein, Altaire pharmaceuticals, INC, Aquebogue NY). Written informed consent was taken from the patient, clearly explaining all potential risks and possible benefits of treatment with intravitreal injections of RBZ. The patient was treated according to the standard operating regulations of the hospital, with antiseptic conjunctival flushusing 3 % Povidone iodine before the injection. Sterile marker was used to mark the sclera at the 4mm post-limbal superior temporal sector. LUCENTIS (ranibizumab injection) designed for intraocular use. 49
5 TREATMENT CRITERIA Chronic CSC requires a tailored and delicate treatment approach that addresses the sites of leakage and the state of the RPE. Distinguish between acute CSC and chronic CSC was not really done in literature, although there is a general belief that such a distinction would correlate with the long-term visual prognosis as well as the decision of whether to treat or wait and when to start treatment. The treatment rationale is based on the ability to decrease fluid from retina s ALS because the pharmacodynamics and pharmacological pathway of RBZ in CSC is poorly understood. The drug penetrates all retinal layers including the RPE, with the complications, such as choriocapillaris damage, RPE atrophy, or ganglion cell damage after long-term successive treatment In spite of this complication absolute and migrating scotoma associated with the current treatment options, conventional thermal laser photocoagulation or photodynamic therapy (PDT), both SDM photocoagulation and intravitreal injections of RBZ offer a better modality of treatment in term of its clinical effectiveness and intra/ postoperative safety profile and, in our view, may potentially represent better treatment modalities. Both ranibizumab and bevacizumab, which are derived from the same parent molecule, inhibit all isoforms of VEGF. However, molecular and pharmacologic properties of these agents differ in several aspects. In an experimental animal model 49, ranibizumab has been shown to penetrate the choroid rapidly after an intravitreal injection. Bevacizumab is a three times larger molecule. Investigations, however, have proven the presence of bevacizumab throughout the neural retina, in the subretinal space and choriocapillaris within 24 hours of Intravitreal injection. In our case, chronic CSC (7years) was successfully treated with 2.5 mg of single dose intravitreal ranibizumab injection. One week later, subretinal fluid was completely resolved and the vision improved to 20/25 and remained stable within one year. OCT after 10 days from injection shows complete absorbtion of the submacular fluid with improvement of vision more than 4 lines. DISCUSSION CSC is characterized by idiopathic serous detachment of the neurosensory retina. There are three theories on CSC pathogenesis: Disorder of the outer BRB, which leads to choroidal vascular hyperpermeability Dysfunction of the RPE with a reversal of liquid transport. 3. Damage of RPE due to shedding of outer photoreceptor segments with a primary intact BRB. Clinical improvement in VA can only be achieved with resolution of subretinal fluid. The state of the RPE is crucial in the pathophysiology and prognosis of the disease itself, and should be taken into consideration for active treatment. Focal laser treatment, the oldest and still questionable therapeutic option is only effective for the coagulation of the ALS on FA 56. Damage to the neurosensory retina by the thermal effect of laser make it only possible in treating extrafoveal sites with putting in consideration to minimize the lazer induced absolute scotomata. Contrast sensitivity loss, accidental foveal damage, retinal distortion, rupture of Bruch s membrane, and choroidal neovascularization are also main complication of thermal effect of laser 57. PDT is used when the RPE lesion is juxta-foveal or subfoveal. PDT counteracts the choroidal hyperperfusion which is the hallmark of CSC development due to local choroidal thrombosis. Studies have shown that intravitreal anti-vegf agents effectively resorb subretinal fluid in up to 80% of the cases 2. One of the most thorough studies on 50
6 the intravitreal injection of BCZ treatment in CSC to date which compared it with SDM photocoagulation, intravitreal BCZ seems to reduce subretinal fluid faster, but requires frequent reinjections, regardless of the dosage, they used 1.25 mg of BCZ In as described by Inoue et al, 58 whereas some groups 5 mg. 2,59. CSC, unlike in exudative AMD, intravitreal anti-vegf injections were not associated with long-term damage to the RPE, the choriocapillaris, or the ganglion cells. However, CSC patients are usually younger, and ongoing intravitreal injections might not be a sustainable therapy. CONCLUSION Intravitreal Anti-VEGF proved to be an easy, safe and effective new method of CSC treatment even in chronic cases and comes to be superior to conventional methods of treatment like: o Laser photo coagulation o Transpupillary thermotherapy o Photodynamic therapy And this gives new indication added to the indications of use of intravitreal Anti- VFGF. REFERENCES 1. Taban M, Boyer DS, Thomas EL. Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol. 2004;137(6): Artunay O, Yuzbasioglu E, Rasier R, et al. Intravitrealbevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res. 2010;35(2): Chan WM, Lam DS, Lai TY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003;87(12): Schmidt-Erfurth U, Michels S, Barbazetto I, et al. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002;43: Shin JY, Woo SJ, Yu HG, et al. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2011;31(1): Artunay O, Yuzbasioglu E, Rasier R, et al. Intravitrealbevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res. 2010;35(2): Gass JDM. Pathogenesis of disciform detachment of the neuroepithelium: III. Senile disciform macular degeneration. Am J Ophthalmol. 1967;63: Gass JDM. Pathogenesis of disciform detachment of the neuroepithelium: IV. Fluorescein angiographic study of senile disciform macular degeneration. Am J Ophthalmol. 1967;63: Gass JDM. Pathogenesis of disciform detachment of the neuroepithelium: V. Disciform macular detachment secondary to focal choroiditis. Am J Ophthalmol. 1967;63: Ryan SJ. Central serous chorioretinopathy. Retina 3rd edn. 2001;2: Fuchs E. Ein Fall von zentraler residivierender syphilitischer Netzhaut Enzundung. Zentralbl Prakt Augenheilkd. 1916; 40: Guist G. Ueberpreretinales Oedema. Z Augenheilkd. 1925;54: Kitahara S. Ueberklinische Beobachtungenbei der in Japan haufigvorkommenden Chorioretinitissentralis serosa. Klin Monatsbl Augenheilkd. 1936;97: Reiger H. Zur Atiologic der Retinitis exudative externacentralis. Albrecht Von Graefes Arch Klin Exp Ophthalmol Djakri SE, Dilinas N. L importance de la lambliase comme facteur etiologique dans la chorioretinite central sereuse. Ophthalmologica. 1963;147: Si-Boen-Lian. The etiologic agent of central serous central chorioretinitis. Ophthalmologica. 1964;148: Ko HU. An experimental study of the nature of Masuda s chorioretinitis: III. A study of the relationship existing between chorioretinitis centralis photodynamica and the function of the kidney. Acta Soc Ophthalmol Jpn. 1934;38: Redman SI. A review of solar retinitis as it may pertain to macular lesions seen in persons of the armed forces. Am J Ophthalmol. 1945;28:
7 19. Delman M, Leubuscher K. Transient macular edema due to griseofulvin. Am J Ophthalmol. 1963;56: Haynes SB, Levine S, Scotch NA, et al. The relationship of psychological factors to coronary heart disease in the Framingham Study: I. Methods and risk factors. Am J Epidemiol. 1978;107: Burton T. Central serous retinopathy. In: FC Blodi (ed) Current Concepts in Ophthalmology. St Louis: CV Mosby; 1972, pp Bettman JW. Allergic retinosis. Am J Ophthalmol. 1945;28: Lothman L. Clinical Manifestations of Allergy in Ophthalmology Year Book of EENT. Year Book Medical Publishers: Chicago; 1941: Berens C, Sayad WY, Girard LJ. Symposium on ocular allergy. The uveal tract and retina: consideration of certain experimental and clinical concepts. Trans Am Acad Ophthalmol Otolaryngol. 1952;56: Hassan L, Carvalho C, Yannuzzi LA, et al. Central serous chorioretinopathy in a patient using methylenedioxymethamphetamine (MDMA) or ecstasy. Retina. 2001;21: Nagayoshi K. Experimental study of chorioretinopathy by intravenous injection of adrenaline. Nippon Ganka Gakkai Zasshi. 1971;75: Yoshioka H, Sugita T, Nagayoshi K. Fluorescein angiographic findings in experimental retinopathy produced by intravenous adrenaline injection. Preliminary report. Nippon Ganka Kiyo. 1970;21: Guyer DR, Yannuzzi LA, Slakter JS, et al. Digital indocyanine-green videoangiography of central serous chorioretinopathy. Arch Ophthalmol. 1994;112: Giovannini A, Scassellati-Sforzolini B, D Altobrando, et al. Choroidal findings in the course of idiopathic serous pigment epithelial detachment detected by indocyanine green videoangiography. Retina. 1997;17: Wakakura M, Ishikawa S. Central serous chorioretinopathy complicating systemic corticosteroid treatment. Br J Ophthalomol. 1984;68: Polak BCP, Baarsma GS, Snyers B. Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment. Br J Ophthalomol. 1995;79: Heimovici R, Gragoudas ES, Duker JS, et al. Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids. Ophthalmology. 1997;104: Garg SP, Dada T, Talwar D, et al. Endogenous cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalomol. 1997;81: Bouzas EA, Scott MH, Mastorakos G, et al. Central serous chorioretinopathy in edogenoushypercortisolism. Arch Ophthalmol. 1993;111: Chan WM, Lam DS, Lai TY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green angiography guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 2003;87: Gonzalez C. Décollementsséreuxretiniens. J Fr Ophthalmol. 1992;15: Robertson DM, Ilstrup D. Direct, indirect and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983;95: Burumcek E, Mudun A, Karakocoglu S, et al. Laser photocoagulation for persistent central serous retinopathy: results of lonf term follow-up. Ophthalmology. 1997;104: Yap EY, Robertson DM. The long-term outcome of central serous chorioretinopathy. Arch Ophthalmol. 1996;114: Huang WC, Chen WL, Tsai YY, et al. Intravitrealbevacizumab for treatment of chronic central serous chorioretinopathy. Eye. 2009; 23(2): Cardillo Piccolino F, Eandi CM, Ventre L, et al. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003; 23: Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography- guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003;23: Chan WM, Lam DS, Lai TY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green angiography guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003; 87: Torres-Soriano ME, García-Aguirre G, Kon-Jara V, et al. A pilot study of intravitrealbevacizumab for the treatment of central serous chorioretinopathy (Case reports). Graefes Arch Clin Exp Ophthalmol. 2008; 246:
8 45. Seong HK, Bae JH, Kim ES, et al. Intravitrealbevacizumab to treat acute central serous chorioretinopathy: short-term effect. Ophthalmologica. 2009;223: Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol. 2006;290 (2):H547 H Iriyama A, Chen YN, Tamaki Y, et al. Effect of anti-vegf antibody on retinal ganglion cells in rats. Br J Ophthalmol. 2007;91 (9): Kamba T, Tam BY, Hashizume H, et al. VEGFdependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol. 2006;290 (2):H560 H Lanzetta P, Furlan F, Morgante L, et al. Nonvisible subthresholdmicropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. Eur J Ophthalmol. 2008;18(6): Klais CM, Ober MD, Ciardella AP, et al. Central Serous ChorioretinopathyIn: Ryan SJ (ed.).retinavol. IIElsevier: Philadelphia;2006: Guyer DR, Yannuzzi LA, Slakter JS, et al. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol. 1994;112 (8): Carvalho-Recchia CA, Yannuzzi LA, Negrao S, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002;109(10): Mudvari SS, Goff MJ, Fu AD, et al. The natural history of pigment epithelial detachment associated with central serous chorioretinopathy. Retina. 2007;27 (9): Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy. ActaOphthalmol. 2008;86 (2): Yannuzzi LA, Shakin JL, Fisher YL, et al. Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology. 1984;91 (12): Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983;95 (4: Landers MB, III, Shaw HE, Jr, Anderson WB, et al. Argon laser treatment of central serous chorioretinopathy. Ann Ophthalmol. 1977;9(12): Artunay O, Yuzbasioglu E, Rasier R, et al. Intravitrealbevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res. 2010;35(2): Inoue M, Kadonosono K, Watanabe Y, et al. Results of one-year follow-up examinations after intravitrealbevacizumab administration for chronic central serous chorioretinopathy. Ophthalmologica. 2010;225(1):
IQ 532 Micropulse Green Laser treatment for Refractory Chronic Central Serous Retinopathy
Cronicon OPEN ACCESS EC OPHTHALMOLOGY Case Report IQ 532 Micropulse Green Laser treatment for Refractory Chronic Central Serous Retinopathy Fawwaz Al Mamoori* Medical Retina Department, Eye Specialty Hospital,
More informationEvaluation of efficacy of eplerenone in the management of chronic central serous choroidoretinopathy
Original article: Evaluation of efficacy of eplerenone in the management of chronic central serous choroidoretinopathy Dr. Sushant Madaan* Department of Ophthalmology, NIMS Medical College and Hopsital,Jaipur,
More informationCENTRAL SEROUS CHORIORETINOPATHY (CSC) IS
Association Between the Efficacy of Half-Dose Photodynamic Therapy With Indocyanine Green Angiography and Optical Coherence Tomography Findings in the Treatment of Central Serous Chorioretinopathy MASSIMO
More informationPrincipal Investigator: Mårten Brelen, Assistant Professor Department of Ophthalmology & Visual Sciences (DOVS), CUHK
RESEARCH PROTOCOL Title: Subthreshold micropulse yellow (577 nm) laser versus half-dose photodynamic therapy for central serous chorioretinopathy : a randomized controlled pilot study Principal Investigator:
More informationNonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy: A pilot study
European Journal of Ophthalmology / Vol. 18 no. 6, 2008 / pp. 934-940 Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy: A pilot study P. LANZETTA, F.
More informationIntravitreal ranibizumab in the management of acute central serous Chorioretinopathy
Open Access International Journal of Clinical and Experimental Ophthalmology Research Article ISSN 2577-140X Intravitreal ranibizumab in the management of acute central serous Chorioretinopathy Ibrahim
More informationStabilization of visual acuity with photodynamic therapy in eyes with chorioretinal anastomoses
Graefe s Arch Clin Exp Ophthalmol (2004) 242:368 376 CLINICAL INVESTIGATION DOI 10.1007/s00417-003-0844-0 Rufino M. Silva José R. Faria de Abreu António Travassos José G. Cunha-Vaz Stabilization of visual
More information연령연관황반변성에서망막혈관종성증식과동반된망막색소상피박리의임상양상과일차적인광역학치료의결과
연령연관황반변성에서망막혈관종성증식과동반된망막색소상피박리의임상양상과일차적인광역학치료의결과 40 Table. Clinical characteristics and results of patients undergoing photodynamic therapy for retinal angiomatous proliferation Patients No. Age/ sex Eye
More informationDepartment of Ophthalmology, Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea
Department of Ophthalmology, Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea Purpose: To investigate the factors that affect final vision following photodynamic therapy
More informationMichael P. Blair, MD Retina Consultants, Ltd Libertyville/Des Plaines, Illinois Clinical Associate University of Chicago 17 October 2015
Michael P. Blair, MD Retina Consultants, Ltd Libertyville/Des Plaines, Illinois Clinical Associate University of Chicago 17 October 2015 So What Parts of the Eye Retina are Affected by VHL Neural tissue
More informationClinical Characteristics of Polypoidal Choroidal Vasculopathy Associated with Chronic Central Serous Chorioretionopathy
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2012;26(1):15-20 http://dx.doi.org/10.3341/kjo.2012.26.1.15 Original Article Clinical Characteristics of Polypoidal Choroidal Vasculopathy Associated
More informationClinically Significant Macular Edema (CSME)
Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2
More informationMicropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy: A Randomized Pilot Trial
CLINICAL SCIENCE Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy: A Randomized Pilot Trial Luiz Roisman, MD; Fernanda Pedreira Magalhães, MD; Daniel Lavinsky, MD; Nilva Moraes,
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Multivariate Analysis of Intravitreal Injection of Anti-VEGF Bevacizumab in the Treatment
More informationDepartment of Ophthalmology, Faculty of Medicine, Ankara University, Ankara, Turkey
Ophthalmology Volume 2016, Article ID 3513794, 8 pages http://dx.doi.org/10.1155/2016/3513794 Clinical Study Low-Fluence Photodynamic Therapy versus Subthreshold Micropulse Yellow Wavelength Laser in the
More informationTranspupillary thermotherapy for central serous chorioretinopathy
VOL. 32 NO. PHILIPPINE JOURNAL O Ophthalmology JANUARY CASE REPORT JUNE 2007 Harvey S. Uy, D, 2 arlah Angela. Salvosa, D 2 Pik Sha Chan, D Pearl T. Villalon, D 2 Asian Eye Institute akati, Philippines
More informationLOW-INTENSITY/HIGH-DENSITY SUBTHRESHOLD DIODE MICROPULSE LASER FOR CENTRAL SEROUS CHORIORETINOPATHY
LOW-INTENSITY/HIGH-DENSITY SUBTHRESHOLD DIODE MICROPULSE LASER FOR CENTRAL SEROUS CHORIORETINOPATHY JEFFREY K. LUTTRULL, MD Purpose: To review the results of low-intensity/high-density subthreshold micropulse
More informationDespite our growing knowledge of the
OVERVIEW OF AVAILABLE TREATMENTS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION * Carl D. Regillo, MD ABSTRACT Although potential treatments for neovascular age-related macular degeneration represent
More informationA prospective nonrandomized clinical study on exudative age related macular degeneration
Original Article A prospective nonrandomized clinical study on exudative age related macular degeneration Ayakutty Muni Raja, Siddharam Janti, Charanya Chendilnathan, Adnan Matheen Department of Ophthalmology,
More informationRetina Conference. Janelle Fassbender, MD, PhD University of Louisville Department of Ophthalmology and Visual Sciences 09/04/2014
Retina Conference Janelle Fassbender, MD, PhD University of Louisville Department of Ophthalmology and Visual Sciences 09/04/2014 Subjective CC/HPI: 64 year old Caucasian female referred by outside ophthalmologist
More informationHigh-dose antioxidants for central serous chorioretinopathy; The randomized placebo-controlled study
Ratanasukon et al. BMC Ophthalmology 2012, 12:20 RESEARCH ARTICLE Open Access High-dose antioxidants for central serous chorioretinopathy; The randomized placebo-controlled study Mansing Ratanasukon *,
More informationTranspupillary thermotherapy for subfoveal leaks in central serous chorioretinopathy
(2008) 22, 100 106 & 2008 Nature Publishing Group All rights reserved 0950-222X/08 $30.00 www.nature.com/eye CLINICAL STUDY Transpupillary thermotherapy for subfoveal leaks in central serous chorioretinopathy
More informationAuthors. Introduction. Introduction. Materials and Methods. Objective 10/27/2015
Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) in Thai Population Presenting with Choroidal Neovascularization (CNV) A multicenter study Authors Yonrawee Piyacomn 1, Chavakij Bhoomibunchoo 1, Yosanan
More informationSpontaneous Large Serous Retinal Pigment Epithelial Tear
This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the article
More informationTHE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION
THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION MOESTIDJAB DEPARTMENT OF OPHTHALMOLOGY SCHOOL OF MEDICINE AIRLANGGA UNIVERSITY DR SOETOMO HOSPITAL SURABAYA INTRODUCTION
More informationIndocyanine Green Angiography Findings in Central Serous Chorioretinopathy
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 5 Ver. III (May. 2016), PP 11-21 www.iosrjournals.org Indocyanine Green Angiography Findings
More informationCentral Serous Choroidopathy-An Overview
Central Serous Choroidopathy-An Overview Dr.Aparajita Banerjee 1, Dr. Sucheta Parija 2 1 Senior Resident, 2 Associate Professor, AIIMS Bhubaneswar Introduction Central serous chorioretinopathy (CSCR) is
More informationCase Report Increase in Central Retinal Edema after Subthreshold Diode Micropulse Laser Treatment of Chronic Central Serous Chorioretinopathy
Case Reports in Ophthalmological Medicine Volume 2015, Article ID 813414, 4 pages http://dx.doi.org/10.1155/2015/813414 Case Report Increase in Central Retinal Edema after Subthreshold Diode Micropulse
More informationAcknowledgements. Outline. Who were von Hippel and Lindau? Eugen von Hippel German Ophthalmologist
Ophthalmic Therapies & Standard of Care Acknowledgements Eric Jonasch, MD & Surena Matin, MD Collaborators Franco DeMonte, MD Marcy Johnson Ian McCutcheon, MD Chaan Ng, MD Nancy Perrier, MD Dawid Schellingerhout,
More informationCentral serous chorioretinopathy (CSCR) was
Case Report 777 Perfluorocarbon Liquid-Assisted External Drainage in the Management of Central Serous Chorioretinopathy with Bullous Serous Retinal Detachment Hung-Chiao Chen, MD; Jau-Der Ho, MD; San-Ni
More informationDOME SHAPED MACULOPATHY. Ιωάννης Ν. Βαγγελόπουλος Χειρ. Οφθαλμίατρος - Βόλος
DOME SHAPED MACULOPATHY Ιωάννης Ν. Βαγγελόπουλος Χειρ. Οφθαλμίατρος - Βόλος DOME SHAPED MACULOPATHY-DEFINITIONS The entity Dome Shaped Macula ( DSM ) was first described by Gaucher and associates in 2008
More informationThe limited number of currently approved
CLINICAL TRIALS OF VERTEPORFIN AND PEGAPTANIB: WHAT ARE THE RESULTS? * William F. Mieler, MD ABSTRACT Currently available treatment options for the management of choroidal neovascularization (CNV) in age-related
More informationI diopathic central serous (chorio)retinopathy (CSR) is a
1483 EXTENDED REPORT Evaluation of central serous retinopathy with en face optical coherence tomography M E J van Velthoven, F D Verbraak, P M Garcia, R O Schlingemann, R B Rosen, M D de Smet... See end
More information11/29/2016 MACULAR MALADIES: TYPICAL & ATYPICAL CASES
MACULAR MALADIES: TYPICAL & ATYPICAL CASES Dawn Pewitt, OD, FAAO Triad Eye Institute, Grove, OK Dpewitt@triadeye.com Disclosure Statement: No financial disclosures COPE 51218-PS Please silence all mobile
More informationClinical Case Presentation. Branch Retinal Vein Occlusion. Sarita M. Registered Nurse Whangarei Base Hospital
Clinical Case Presentation on Branch Retinal Vein Occlusion Sarita M. Registered Nurse Whangarei Base Hospital Introduction Case Study Pathogenesis Clinical Features Investigations Treatment Follow-up
More informationZEISS AngioPlex OCT Angiography. Clinical Case Reports
Clinical Case Reports Proliferative Diabetic Retinopathy (PDR) Case Report 969 PROLIFERATIVE DIABETIC RETINOPATHY 1 1-year-old diabetic female presents for follow-up of proliferative diabetic retinopathy
More informationFluorescein Angiography
Last revision: October 2011 by Luis Arias Fluorescein Angiography Authors: Luis Arias, MD Hospital Universitari de Bellvitge - University of Barcelona. Spain Jordi Monés, MD Institut de la Màcula i de
More informationOphthalmology Macular Pathways
Ophthalmology Macular Pathways Age related Macular Degeneration Diabetic Macular Oedema Macular Oedema secondary to Central Retinal Macular Oedema secondary to Branch Retinal CNV associated with pathological
More informationMONTHLY ADMINISTERED INTRAVITREOUS PHARmacotherapy
Polypoidal Choroidal Vasculopathy Masquerading as Neovascular Age-Related Macular Degeneration Refractory to Ranibizumab ALEXANDROS N. STANGOS, JAGDEEP SINGH GANDHI, JAYASHREE NAIR-SAHNI, HEINRICH HEIMANN,
More informationDescription. Section: Other Effective Date: July 15, Subsection: Vision Original Policy Date: December 7, 2011 Subject: Page: 1 of 23
Last Review Status/Date: June 2015 Page: 1 of 23 Description Photodynamic therapy (PDT) is a treatment modality designed to selectively occlude ocular choroidal neovascular tissue. The therapy is a 2-step
More informationMisdiagnosed Vogt-Koyanagi-Harada (VKH) disease and atypical central serous chorioretinopathy (CSC)
HPTER 12 Misdiagnosed Vogt-Koyanagi-Harada (VKH) disease and atypical central serous chorioretinopathy (S) linical Features VKH disease is a bilateral granulomatous panuveitis often associated with exudative
More informationEfficacy of Anti-VEGF Agents in the Treatment of Age-Related Macular Degeneration
Efficacy of Anti-VEGF Agents in the Treatment of Age-Related Macular Degeneration Marilita M. Moschos Abstract- Purpose: To evaluate by OCT and mf-erg the macular function in eyes with CNV due to ARMD
More informationMitsuko Yuzawa,* Takako Isomae,* Ryuzaburo Mori,* Hiroyuki Shimada* and Izumi Utsunomiya
Surgical Excision Versus Laser Photocoagulation for Subfoveal Choroidal Neovascular Membrane with Age-related Macular Degeneration: Comparison of Visual Outcomes Mitsuko Yuzawa,* Takako Isomae,* Ryuzaburo
More informationOCT Angiography in Primary Eye Care
OCT Angiography in Primary Eye Care An Image Interpretation Primer Julie Rodman, OD, MS, FAAO and Nadia Waheed, MD, MPH Table of Contents Diabetic Retinopathy 3-6 Choroidal Neovascularization 7-9 Central
More informationKey words: Choroidal neovascularisation, Laser coagulation, Retinal imaging
420 Mini Review The Role of Optical Coherence Tomography (OCT) in the Diagnosis and Management of Retinal Angiomatous Proliferation (RAP) in Patients with Age-related Macular Degeneration Antonio Polito,
More informationMulti-Modal Longitudinal Evaluation of Subthreshold Laser Lesions in Human Retina, Including Scanning Laser Ophthalmoscope-Adaptive Optics Imaging
EXPERIMENTAL SCIENCE Multi-Modal Longitudinal Evaluation of Subthreshold Laser Lesions in Human Retina, Including Scanning Laser Ophthalmoscope-Adaptive Optics Imaging Edward H. Wood, MD; Theodore Leng,
More informationSystemic Factors Associated with Central Serous Chorioretinopathy in Koreans
pissn: 1011-892 eissn: 92-9382 Korean J Ophthalmol 12;26():260-26 http://dx.doi.org/10.331/kjo.12.26..260 Original Article Systemic Factors Associated with Central Serous Chorioretinopathy in Koreans Youngsub
More informationFEEDER VESSEL TREATMENT
THERAPEUTIC OPTIONS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION * Discussion led by Donald J. D'Amico, MD Dr D Amico: The overview articles in this monograph highlight findings from clinical trials
More informationPhotodynamic Therapy for Choroidal Neovascularization
Photodynamic Therapy for Choroidal Neovascularization Policy Number: 9.03.08 Last Review: 10/2014 Origination: 10/2000 Next Review: 10/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationMEDICAL POLICY SUBJECT: PHOTODYNAMIC THERAPY FOR EFFECTIVE DATE: 07/20/00 SUBFOVEAL CHOROIDAL NEOVASCULARIZATION
MEDICAL POLICY SUBJECT: PHOTODYNAMIC THERAPY FOR PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationTHE OCULAR histoplasmosis
CLINICAL SCIENCES Reactivation of Inflammatory Lesions in Ocular Histoplasmosis David Callanan, MD; Gary E. Fish, MD, JD; Rajiv Anand, MD Background: Active inflammation has not been traditionally associated
More informationDescription. Section: Other Effective Date: July 15, Subsection: Vision Original Policy Date: September 13, 2011 Subject: Page: 1 of 18
Last Review Status/Date: June 2014 Page: 1 of 18 Description Angiogenesis inhibitors (e.g., ranibizumab, bevacizumab, pegaptanib, aflibercept) are being evaluated for the treatment of disorders of choroidal
More informationAlthough photocoagulation and photodynamic PROCEEDINGS PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION *
PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION Evangelos S. Gragoudas, MD ABSTRACT In December 24, the US Food and Drug Administration (FDA) approved pegaptanib sodium. Pegaptanib
More informationLong-term Management of AMD. Motasem Al-latayfeh, MD Assistant Prof. Ophthalmology Hashemite University Jordan
Long-term Management of AMD Motasem Al-latayfeh, MD Assistant Prof. Ophthalmology Hashemite University Jordan DEFINITION 1 Age-related macular degeneration (AMD) is a disorder of the macula characterized
More informationPolypoidal choroidal vasculopathy and photodynamic therapy with verteporfin
Graefe s Arch Clin Exp Ophthalmol (2005) 243: 973 979 CLINICAL INVESTIGATION DOI 10.1007/s00417-005-1139-4 Rufino M. Silva João Figueira M. Luz Cachulo Liliane Duarte José R. Faria de Abreu J. G. Cunha-Vaz
More informationAnti VEGF Agents in Retinal Disorders Current Scenario
Retina Anti VEGF Agents in Retinal Disorders Current Scenario Charu Gupta MS Charu Gupta MS, Cyrus M. Shroff MD Shroff Eye Centre, New Delhi T is a group of proteins involved in the regulation of angiogenesis,
More informationmeasure of your overall performance. An isolated glucose test is helpful to let you know what your sugar level is at one moment, but it doesn t tell you whether or not your diabetes is under adequate control
More informationHHS Public Access Author manuscript Ophthalmic Surg Lasers Imaging Retina. Author manuscript; available in PMC 2016 January 14.
High-Speed Ultrahigh-Resolution OCT of Bruch s Membrane in Membranoproliferative Glomerulonephritis Type 2 Mehreen Adhi, MD, Sarah P. Read, MD, PhD, Jonathan J. Liu, PhD, James G. Fujimoto, PhD, and Jay
More informationBilateral Elevated Macular Lesions
Challenging Case Bilateral Elevated Macular Lesions Section Editor: Alireza Ramezani, MD Case presentation A 65-year-old woman presented with decreased vision in both eyes of 2 months duration. She reported
More informationTranspupillary thermotherapy (TTT) for the treatment of choroidal neovascularisation
Br J Ophthalmol 2001;85:173 178 173 King s College Hospital, Denmark Hill, London SE5 9RS, UK R S B Newsom J C McAlister M Saeed J D A McHugh Correspondence to: Mr R S B Newsom, Department of Vitreoretinal
More informationAge-Related Macular Degeneration (AMD)
Age-Related Macular Degeneration (AMD) What is the Macula? What is Dry AMD (Age-related Macular Degeneration)? Dry AMD is an aging process that causes accumulation of waste product under the macula leading
More informationCurrent indications for photodynamic therapy in medical retina practice
réalités Current indications for photodynamic therapy in medical retina practice No. 254 September 2018 OPHTALMOLOGIQUES SUMMARY: In medical retina practice, the use of photodynamic therapy (PDT) revolutionised
More informationRetinal Complications of Obstructive Sleep Apnea A Growing Concern!
Retinal Complications of Obstructive Sleep Apnea A Growing Concern! Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl
More informationUpdate on Retina. Gokul Kumar, MD Central Florida Retina October 1, 2017
Update on Retina Gokul Kumar, MD Central Florida Retina October 1, 2017 Overview Part 1: The Changing Landscape of Central Serous Chorioretinopathy and Related Disorders CSR, Pachychoroid Disease Spectrum
More informationMacular Hole Associated with Vogt-Koyanagi-Harada Disease at the Acute Uveitic Stage
Published online: September 15, 2015 2015 The Author(s) Published by S. Karger AG, Basel 1663 2699/15/0063 0328$39.50/0 This article is licensed under the Creative Commons Attribution-NonCommercial 4.0
More informationStudy of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema
Original Research Article Study of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema Neha Kantilal Desai 1,*, Somesh Vedprakash Aggarwal 2, Sonali
More informationA Review of Subthreshold Micropulse Laser for Treatment of Macular Disorders
Adv Ther (2017) 34:1528 1555 DOI 10.1007/s12325-017-0559-y REVIEW A Review of Subthreshold Micropulse Laser for Treatment of Macular Disorders Paula Scholz. Lebriz Altay. Sascha Fauser Received: March
More informationFactors Influencing the Visual Acuity of Chronic Central Serous Chorioretinopathy
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2011;25(2):90-97 DOI: 10.3341/kjo.2011.25.2.90 Factors Influencing the Visual Acuity of Chronic Central Serous Chorioretinopathy Original Article Yun
More informationRetinal Pigment Epithelial Tears (Rips) in the ERA of Anti Vegf - When and Why?
Original Article Retinal Pigment Epithelial Tears (Rips) in the ERA of Anti Vegf - When and Why? Dr Sreelekha S. MS, DNB, DO, FRCS, Dr Manoj Soman DNB, FICO, FRCS, Dr. Unni Nair MS, FRCS, Dr. Ruminder
More informationFeatures of central serous chorioretinopathy presenting at a tertiary care hospital in Lahore
Introduction Central serous chorioretinopathy (CSCR) is the serous detachment of the neurosensory retina (Figure-1). CSCR is one of the 10 most common conditions that affect the macula.1it commonly occurs
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Last Review: September 2016 Next Review: September 2017 Related Policies 9.03.20 Intraocular Radiation Therapy for Age-Related Macular Degeneration Photodynamic Therapy for Choroidal
More informationThe Foundation WHAT IS THE RETINA?
Age-Related Macular Degeneration (AMD) is a deterioration of the retina and choroid that leads to a substantial loss in visual acuity (sharpness of vision). AMD is the leading cause of significant visual
More informationOptical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D.
Optical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D. Disclosure OCT Optical Coherence Tomography No relevant financial relationships I will refer to
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 12 September 2007 INFRACYANINE 25 mg/10 ml, powder and solvent for solution for injection 25 mg vial with one 10 ml
More informationlaser photocoagulation in the treatment of central
British Journal of Ophthalmology, 1988, 72, 829-834 Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy LINDA FICKER, GILLIAN VAFIDIS,
More informationSUMMARY. Heather Casparis, MD,* and Neil M. Bressler, MD MARINA AND ANCHOR
The following are summaries of selected presentations and posters from the American Society of Retina Specialists and European VitreoRetinal Society Annual Meeting held September 9 13, 2006, in Cannes,
More informationPhotodynamic Therapy for Treatment of Subfoveal Choroidal Neovascularization in Exudative Age-Related Macular Degeneration
Clinical Medicine Journal Vol. 4, No. 4, 2018, pp. 60-66 http://www.aiscience.org/journal/cmj ISSN: 2381-7631 (Print); ISSN: 2381-764X (Online) Photodynamic Therapy for Treatment of Subfoveal Choroidal
More informationI n the Western world, age related macular degeneration
207 SCIENTIFIC REPORT Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy F Gelisken, B A Lafaut, W Inhoffen, M Voelker, S Grisanti, K U Bartz-Schmidt...
More informationRetinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration.
Thomas Jefferson University Jefferson Digital Commons Wills Eye Institute Papers Wills Eye Institute 4-1-2008 Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related
More informationEFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY
EFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY Diwakar chaudhary *1, 2, Hu shuqiong, Long Yuan and Xiong kun 1 Yangtze University, 1 Nanhuan Road
More informationCan intravitreal tissue plasminogen activator and SF6 gas facilitate management of macular degeneration with photodynamic therapy?
European Journal of Ophthalmology / Vol. 18 no. 4, 2008 / pp. 591-594 Can intravitreal tissue plasminogen activator and SF6 gas facilitate management of macular degeneration with photodynamic therapy?
More informationVISUAL OUTCOME IN DIABETIC MACULAR EDEMA AFTER GRID LASER TREATMENT
The Professional Medical Journal DOI: 10.17957/TPMJ/16.2856 ORIGINAL PROF-2856 VISUAL OUTCOME IN DIABETIC MACULAR EDEMA AFTER GRID LASER TREATMENT 1. MBBS.FCPS Assistant Professor Ophthalmology Independent
More informationAn A to Z guide on Epiretinal Membranes (ERMs) Paris Tranos PhD,ICO,FRCS OPHTHALMICA Vitreoretinal & Uveitis Department
An A to Z guide on Epiretinal Membranes (ERMs) Paris Tranos PhD,ICO,FRCS OPHTHALMICA Vitreoretinal & Uveitis Department Types of ERM Natural history OCT prognostic factors ERM with co-existing pathology
More informationCase Report: Indocyanine Green Dye Leakage from Retinal Artery in Branch Retinal Vein Occlusion
Case Report: Indocyanine Green Dye Leakage from Retinal Artery in Branch Retinal Vein Occlusion Hiroki Fujita, Kyoko Ohno-Matsui, Soh Futagami and Takashi Tokoro Department of Visual Science, Tokyo Medical
More informationMacular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials
Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials Glenn J. Jaffe, MD, 1 Daniel F. Martin, MD, 2 Cynthia A. Toth, MD, 1 Ebenezer Daniel, MPH, PhD,
More informationUpdate on Central Serous Chorioretinopathy
Update on Central Serous Chorioretinopathy Steve Bennett Retina Update 2017 No financial interest Off label use of Spironolactone, Eplerenone, Melatonin, Verteporfin, Rifampin 1 2 Classic Central Serous
More informationDepartment of Ophthalmology, University Hospital of Santiago de Compostela, Ramon Baltar S/N, Santiago de Compostela, Spain 2
Case Reports in Medicine Volume 2012, Article ID 897097, 10 pages doi:10.1155/2012/897097 Case Report Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy
More informationSeokhyun Bae, Kiwon Jin, Hakyoung Kim and So Hyun Bae *
Bae et al. BMC Ophthalmology (2015) 15:180 DOI 10.1186/s12886-015-0170-4 RESEARCH ARTICLE Open Access Clinical parameters related to metamorphopsia outcome in patients with resolved central serous chorioretinopathy
More informationThe Era of anti- - - VEGF Kirk L. Halvorson, OD
The Era of anti- - - VEGF Kirk L. Halvorson, OD Introduction: Anti- - - Vascular Endothelial Growth Factor (Anti- - - VEGF) medication is a relatively a new line of medications used in treating a variety
More informationSince /01/2014 Private practice Ophthalmology, Retinal Medical Specialty and AMD, private office
Corinne GONZALEZ Ophthalmology (MD, Ph.D ) Retinal Medical Specialist SELARL CABINET DOCTEUR GONZALEZ 27, Boulevard des Minimes 31 200 Toulouse! 05 34 40 77 30 e-mail : cabinet.dr.gonzalez@wanadoo.fr Fax
More informationPhotocoagulation of disciform macular lesions
British Journal of Ophthalmology, 1979, 63, 669-673 Photocoagulation of disciform macular lesions with krypton laser A. C. BIRD AND R. H. B. GREY From the Institute of Ophthalmology, Moorfields Eye Hospital,
More informationComparative Study of Experimental Choroidal Neovascularization by Optical Coherence Tomography and Histopathology
Comparative Study of Experimental Choroidal Neovascularization by Optical Coherence Tomography and Histopathology Toshio Fukuchi, Kanji Takahashi, Masanobu Uyama and Miyo Matsumura Department of Ophthalmology,
More informationPhotodynamic therapy (PDT) for Central Serous Retinopathy (CSR)/ Polypoidal Choroidal Vasculopathy (PCV)
Photodynamic therapy (PDT) for Central Serous Retinopathy (CSR)/ Polypoidal Choroidal Vasculopathy (PCV) About photodynamic therapy for Retinal Conditions The macula is the central part of the retina at
More informationClinical Policy: Neovascular (WET) Macular Degeneration Treatment Reference Number: CP.MP.283
Clinical Policy: Neovascular (WET) Macular Degeneration Treatment Reference Number: CP.MP.283 Effective Date: 11/16 Last Review Date: 11/17 See Important Reminder at the end of this policy for important
More informationVMA at the macula resulting in VMT
Ocriplasmina for pharmacologic treatment in VMT Teresio Avitabile 1 Introduction PVD is a normal, physiologic process that occurs with aging; however, in some cases, PVD is incomplete Incomplete PVD localized
More informationROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS
ORIGINAL ARTICLE ROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS Aggarwal Somesh VP 1, Shah Sonali N 2, Bharwada Rekha M 3,
More informationClinical Features of Bilateral Acute Idiopathic Maculopathy
Clinical Features of Bilateral Acute Idiopathic Maculopathy Toru Nakazawa,, Katsuhiro Yamaguchi, Masahiko Shimura, Madoka Yoshida, Yuki Yoshioka and Makoto Tamai Department of Ophthalmology, Katta General
More informationCase Report Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex)
Case Reports in Ophthalmological Medicine, Article ID 231913, 5 pages http://dx.doi.org/10.1155/2014/231913 Case Report Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone
More informationAbstract Aims To analyse the histopathology of classic and occult choroidal neovascular membrane surgical specimens in age
Br J Ophthalmol 2000;84:239 243 239 ORIGINAL ARTICLES Clinical science Clinicopathological correlation in exudative age related macular degeneration: histological diverentiation between classic and occult
More information